Reshape Lifesciences Shareholders Approve Merger with Vyome Therapeutics, Trading to Begin August 15

Reshape’s Shareholders Cleared the Required Approvals to Officialize the Merger with Vyome

Announcement

Reshape Lifesciences shareholders ticked all proposals required for the completion of the previously introduced alliance with Vyome Therapeutics. The partnership will be officially effective for trading on 15th August 2025. The shares of the common stock of merged companies will be reinforced trading on the Nasdaq Capital Market in the name of Vyome Holdings, Inc., and the ‘hind’ will be the trading symbol. Reshape is America’s premier weight loss and metabolic health-solutions industry, and Vyome is a developing healthcare platform covering the US-India innovation corridor.

The specialization of both companies will flourish and add their valuable contribution to the massive healthcare market. This collaboration will fuel development in the US and India regions. The innovative bridge to both regions will experience growth through this strategic alliance. The commencement of the trading will uplift capitalization to the specific region considered under this partnership and stabilize the economy and financial flow of the region's development, accordingly.

The Representatives of Reshape

The Maxim Group LLC is delivering as a financial advisor to reshape in a merger with the Fox Rothschild LLP and transactions enacted as legal counsel. Chardan will be a financial advisor to Vyome for the alliance and Sichenzia Ross Ference Carmel LLP as its legal counsel. Their expertise will fuel the strategies planned for this partnership and further build a robust foundation seeking a valuable and profitable future for both companies.

Views and Statements from the Company’s Leaders

Chairman of Vyome, Krishna Gupta, said, “Vyome’s motive and vision are to expand with various promising assets and aim to form a robust healthcare platform covering the US-India innovation spectrum. We’re looking forward to trading as a public company under the ticker symbol ‘hind’, which we expect to be effective on this year's Independence Day, 15th August 2025. We have a developed and entrepreneurial mindset management and board team, and a deep understanding of value creation for our new and existing shareholders.”

Chief executive officer of Reshape, Paul Hickey, expressed his excitement, saying, “We are thankful for this warm support from our shareholders for this alliance with Vyome and the sale of our assets to Biorad Medisys. Vyome is a well-deserved company for success, and we believe this transaction will provide a competitive opportunity for our shareholders while Vyome retains its growth strategy as a Nasdaq-listed public company.”